Abstract
The project aims to improve the differential dementia diagnosis using cerebrospinal fluid (CSF) biomarkers by increasing our insight in the overlap of the existing core AD CSF biomarkers between AD and non-AD dementias. Considering the large inter-individual variability in Aβ load, normalizing CSF Aβ1-42 to the most abundant and stably produced Aβ isoform, i.e. Aβ1-40, may enable the diagnosis of high Aβ-producing AD patients ('false negatives') or low Aβ-producing non-AD patients ('false positives') by calculation of the Aβ1-42/Aβ1-40 ratio. The clinical/autopsy confirmed cohort consist of 50 AD patients with an AD suggestive biomarker profile (high T-tau and or P-tau181 and low Aβ1-42), 50 AD patients with normal Aβ1-42 levels, 50 non-AD patients with low Aβ1-42 levels and 50 controls; a total of 200 patients. The amyloid marker Aβ1-42 will be reanalyzed to minimize analytical confounding factors and Aβ1-40 will be analyzed in the same CSF patient samples. The diagnostic accuracy of the Aβ1-42/Aβ1-40 ratio will be assessed in comparison to the Aβ1-42 alone. The ratio is expected to improve the diagnostic accuracy.
Researcher(s)
Research team(s)
Project type(s)